secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOLASE, INC (—)
CIK:        0000811240
Form:       8-K
Filed at:   2023-01-12T23:59:59+00:00
Accession:  0001193125-23-006843
Event type: regulatory
Sentiment:  negative
Materiality: 0.60
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

BIOLASE receives Nasdaq bid price deficiency notice; 180 days to cure
---------------------------------------------------------------------

- Common stock closed below $1.00 per share for 30 consecutive business days through Jan 10, 2023.
- Company has 180 calendar days, until July 10, 2023, to regain compliance under Nasdaq Listing Rule 5550(a)(2).
- To regain compliance, bid price must close at $1.00+ for at least 10 consecutive business days before Compliance Date.
- If not cured, may seek additional 180-day period by providing intent to cure, potentially via reverse stock split.
- Company intends to monitor closing bid price and consider available options to regain compliance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/811240/000119312523006843/0001193125-23-006843-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/811240/000119312523006843/d405891d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-006843

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer